Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF – Get Free Report) were up 13.9% during mid-day trading on Monday . The stock traded as high as $0.2660 and last traded at $0.2660. Approximately 171 shares were traded during trading, a decline of 82% from the average daily volume of 973 shares. The stock had previously closed at $0.2335.
Zelira Therapeutics Stock Up 13.9%
The firm’s 50-day moving average is $0.22 and its 200 day moving average is $0.25.
Zelira Therapeutics Company Profile
Zelira Therapeutics Ltd is a clinical-stage biotechnology company focused on the development and commercialization of proprietary cannabinoid-based therapies. The company leverages a portfolio of clinical and preclinical drug candidates designed to address unmet medical needs in areas such as chronic pain, autism spectrum disorder, Alzheimer’s disease and sleep disorders. Utilizing patented formulation and delivery platforms, Zelira aims to optimize efficacy and safety profiles of plant-derived cannabinoids.
The company pursues a dual geography strategy through its Australian and North American operations.
Read More
- Five stocks we like better than Zelira Therapeutics
- Wall Street Stockpicker Names #1 Stock of 2026
- Trump’s new AI budget just passed — one stock could soar
- [How To] Claim Your Pre-IPO Stake In SpaceX!
- Drop these 5 stocks now!
- The McDonald’s Secret
Receive News & Ratings for Zelira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zelira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
